Statins, bone, and neurofibromatosis type 1

BMC Medicine

Volumn 6, Issue , 2008, Pages

  Korf, Bruce R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NEUROFIBROMIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; ENZYME ACTIVATOR;

BONE DEVELOPMENT; BONE DYSPLASIA; BONE METABOLISM; DRUG EFFICACY; DRUG SAFETY; FRACTURE HEALING; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; HAPLOIDY; HUMAN; NEUROFIBROMATOSIS; NONHUMAN; NOTE; PHENOTYPE; RECEPTOR BINDING; TIBIAL DYSPLASIA; ANIMAL; EDITORIAL; MOUSE;

ANIMALS; ENZYME ACTIVATORS; HUMANS; LOVASTATIN; MICE; NEUROFIBROMATOSIS 1;

EID: 51349102476     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-6-22     Document Type: Note

References (21)

1. Korf BR Clinical features and pathobiology of neurofibromatosis 1 J Child Neurol 2002, 17:573. 10.1177/088307380201700806 12403555
2. Stevenson DA Birch PH Friedman JM Viskochil DH Balestrazzi P Boni S Buske A Korf BR Niimura M Pivnick EK Schorry EK Short MP Tenconi R Tonsgard JH Carey JC Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1 Am J Med Genet 1999, 84:413. 10.1002/ (SICI)1096-8628(19990611)84:5<413::AID-AJMG5>3.0.CO;2-1 10360395
3. Kuorilehto T Poyhonen M Bloigu R Heikkinen J Vaananen K Peltonen J Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body Osteoporos Int 2005, 16:928. 10.1007/s00198-004-1801-4 15551055
4. Lammert M Kappler M Mautner VF Lammert K Storkel S Friedman JM Atkins D Decreased bone mineral density in ptients with neurofibromatosis 1 Osteoporos Int 2005, 16:1161. 10.1007/s00198-005-1940-2 15988556
5. Stevenson DA Moyer-Mileur LJ Murray M Slater H Sheng X Carey JC Dube B Viskochil DH Bone mineral density in children and adolescents with neurofibromatosis type 1 J Pediatr 2007, 150:83-88. 1808316 17188620 10.1016/j.jpeds.2006.10.048
6. Yilmaz K Ozmen M Bora Goksan S Eskiyurt N Bone mineral density in children with neurofibromatosis 1 Acta Paediatr 2007, 96:1220-1222. 10.1111/j.1651-2227.2007.00401.x 17608828
7. Serra E Rosenbaum T Winner U Aledo R Ars E Estivill X Lenard HG Lazaro C Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different schwann cell subpopulations Hum Mol Genet 2000, 9:3055. 10.1093/hmg/9.20.3055 11115850
8. Maertens O Brems H Vandesompele J De Raedt T Heyns I Rosenbaum T De Schepper S De Paepe A Mortier G Janssens S Speleman F Legius E Messiaen L Comprehensive NF1 screening on cultured Schwann cells from neurofibromas Hum Mutat 2006, 27:1030-1040. 10.1002/humu.20389 16941471
9. Maertens O De Schepper S Vandesompele J Brems H Heyns I Janssens S Speleman F Legius E Messiaen L molecular dissection of isolated disease features in mosaic neurofibromatosis Type 1 Am J Hum Genet 2007, 81:243-251. 1950809 17668375 10.1086/519562
10. Stevenson DA Zhou H Ashrafi S Messiaen LM Carey JC D'Astous JL Santora SD Viskochil DH Double inactivation of NF1 in tibial pseudarthrosis Am J Hum Genet 2006, 79:143-148. 1474128 16773574 10.1086/504441
11. Silva AJ Elgersma Y Friedman E Stern J Kogan J A mouse model for learning and memory defects associated with neurofibromatosis type I Pathol Biol (Paris) 1998, 46:697. 9885821
12. Costa RM Silva AJ Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1 J Child Neurol 2002, 17:622. 10.1177/088307380201700813 12403561
13. Kuorilehto T Nissinen M Koivunen J Benson MD Peltonen J NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos J Bone Miner Res 2004, 19:983-989. 10.1359/JBMR.040130 15125795
14. Yu X Chen S Potter OL Murthy SM Li J Pulcini JM Ohashi N Winata T Everett ET Ingram D Clapp WD Hock JM Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning Bone 2005, 36:793-802. 10.1016/j.bone.2005.01.022 15804420
15. Wu X Estwick SA Chen S Yu M Ming W Nebesio TD Li Y Yuan J Kapur R Ingram D Yoder MC Yang FC Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells Hum Mol Genet 2006, 15:2837-2845. 10.1093/hmg/ddl208 16893911
16. Kolanczyk M Kossler N Kuhnisch J Lavitas L Stricker S Wilkening U Manjubala I Fratzl P Sporle R Herrmann BG Parada LF Kornak U Mundlos S Multiple roles for neurofibromin in skeletal development and growth Hum Mol Genet 2007, 16:874-886. 10.1093/hmg/ddm032 17317783
17. Barkan B Starinsky S Friedman E Stein R Kloog Y The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1 Clin Caner Res 2006, 12:5533-5542. 10.1158/1078-0432.CCR-06-0792
18. Costa RM Federov NB Kogan JH Murphy GG Stern J Ohno M Kucherlapati R Jacks T Silva AJ Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 Nature 2002, 415:526-530. 10.1038/nature711 11793011
19. Li W Cui Y Kushner SA Brown RA Jentsch JD Frankland PW Cannon TD Silva AJ The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1 Curr Biol 2005, 15:1961-1967. 10.1016/j.cub.2005.09.043 16271875
20. Krab LC de Goede-Bolder A Aarsen FK Pluijm SM Bouman MJ Geest van der JN Lequin M Catsman CE Arts WF Kushner SA Silva AJ de Zeeuw CI Moll HA Elgersma Y Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial JAMA 2008, 300(3):287-294. 10.1001/jama.300.3.287 18632543
21. Kolanczyk Mateusz Kuehnisch Jirko Kossler Nadine Osswald Monika Stumpp Sabine Thurisch Boris Kornak Uwe Mundlos Stefan Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin BMC Medicine 6:21. 18671844 10.1186/1741-7015-6-21